Partnerships and co-selling for agencies: how to productise the offering for healthcare and life sciences
The service design, pricing, and delivery model for running partnerships and co-selling as a productised offering inside a services firm. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install partnerships and co-selling has to reflect that reality from day one.
Partnerships and co-selling is one of the highest-margin offerings an agency can add in 2026. It is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, and clients will pay a premium for the discipline they cannot install themselves.
Productise around outcome, not activity. Sell sourced and influenced pipeline from partners moving to a defined level in a defined window, not a monthly retainer of vague ops.
Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Partnerships and co-selling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.
Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.
Client failure mode: signing MOUs no one operationalises. Write it into the engagement letter as a shared risk, not something you absorb quietly.
The agencies making the most from partnerships and co-selling are the ones with the tightest playbook. Documented, versioned, and improved every quarter.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing partnerships and co-selling properly rather than half-heartedly across three vendors.
Frequently asked questions
Partnerships · healthcare — answered
- Does partnerships and co-selling work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- How should agencies price partnerships and co-selling?
- Outcome-linked base plus a monthly ops fee. Avoid pure retainer.
- What is the minimum delivery pod?
- Strategist, operator, editor. Three roles, not necessarily three headcount at small scale.
- How long is agency onboarding for partnerships and co-selling?
- Two weeks: diagnosis, list, trigger, kill criteria.
- What client behaviour breaks the engagement?
- Signing MOUs no one operationalises — bake shared risk into the contract.
- What is the healthcare specific pitfall with partnerships and co-selling?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under partnerships · healthcare